Company intelligence / Profile preview
Vericel
Cambridge, Massachusetts, United Statesvcel.com ↗
- Ownership
- Public · VCEL
- Employees
- ~357
- Development stage
- Commercial
01
Overview
Vericel markets three main products in the U.S.: MACI® for repair of knee cartilage defects using autologous cultured chondrocytes on a porcine collagen membrane; Epicel® for permanent skin replacement in severe burn patients using cultured epidermal autografts; and NexoBrid®, an enzymatic debridement agent licensed for North America use in severe thermal burns. Both MACI and Epicel are FDA approved and commercially available. NexoBrid received FDA approval for adults in December 2022 and pediatric use in August 2024. The company has a strong clinical record supporting efficacy and safety across its marketed products.
- Therapeutic areas
- CardiovascularDermatologyRheumatology
- Modalities
- Autologous cell therapies (cultured chondrocytes and epidermal cells)Specialty biologics
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Request access →03
Partnerships
Exclusive license with MediWound Ltd. for NexoBrid distribution in North America.
04
Financials
- Market cap
- $2B
- Total revenue
- $77.5M
- Enterprise value
- $1.9B
Beyond the preview
Go deeper on Vericel.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vericel.